Skip to main content
Toggle navigation
Search
Home
Full Schedule
Home
Full Schedule
All Days
Wed, Nov 1
Thu, Nov 2
Fri, Nov 3
On-Demand
Full Schedule
Type here to filter the list
Wednesday, November 1, 2023
8:00 AM – 8:15 AM
ET
Welcome and Introduction
8:00 AM – 8:15 AM
ET
Welcome and Introduction
8:15 AM – 8:50 AM
ET
Session 1: Updates in Rare Ovarian Cancers (Low Grade, Non-Serous Epithelial and Non-Epithelial)
8:15 AM – 8:50 AM
ET
Session 1: Updates in Rare Ovarian Cancers (Low Grade, Non-Serous Epithelial and Non-Epithelial)
Presenter:
Jubilee Brown, MD
– Levine Cancer Institute at Atrium Health Wake Forest University School of Medicine
8:50 AM – 9:00 AM
ET
Live Q&A
8:50 AM – 9:00 AM
ET
Live Q&A
Moderator:
Kathleen N. Moore, MD, MS
– Stephenson Cancer Center, University of Oklahoma Health Sciences Center
Presenter:
Jubilee Brown, MD
– Levine Cancer Institute at Atrium Health Wake Forest University School of Medicine
9:00 AM – 9:15 AM
ET
Break
9:00 AM – 9:15 AM
ET
Break
9:15 AM – 10:00 AM
ET
Session 2: Assessment and Intervention for Chemotherapy-Induced Neuropathy and Myopathy
9:15 AM – 10:00 AM
ET
Session 2: Assessment and Intervention for Chemotherapy-Induced Neuropathy and Myopathy
Presenter:
Elizabeth Hile, PT, PhD
– The University of Oklahoma Health Sciences Center/ OU Health Stephenson Cancer Center
10:00 AM – 10:15 AM
ET
Break
10:00 AM – 10:15 AM
ET
Break
10:15 AM – 11:15 AM
ET
Non-CME Innovation Theater
10:15 AM – 11:15 AM
ET
Non-CME Innovation Theater
11:15 AM – 11:30 AM
ET
Break
11:15 AM – 11:30 AM
ET
Break
11:30 AM – 12:05 PM
ET
Session 3: Management and Challenges of Cervical Cancer Treatment in the Second Line and Beyond
11:30 AM – 12:05 PM
ET
Session 3: Management and Challenges of Cervical Cancer Treatment in the Second Line and Beyond
Presenter:
Debra Richardson, MD
– Stephenson Cancer Center, University of Oklahoma Health Sciences Center
12:05 PM – 12:15 PM
ET
Live Q&A
12:05 PM – 12:15 PM
ET
Live Q&A
Moderator:
Kathleen N. Moore, MD, MS
– Stephenson Cancer Center, University of Oklahoma Health Sciences Center
Presenter:
Debra Richardson, MD
– Stephenson Cancer Center, University of Oklahoma Health Sciences Center
12:15 PM – 12:30 PM
ET
Break
12:15 PM – 12:30 PM
ET
Break
12:30 PM – 1:15 PM
ET
Session 4: Endometrial Cancer Treatment Debate: Checkpoint Inhibitors for All vs Individualized Therapies Beyond Checkpoint Inhibitors
12:30 PM – 12:45 PM
ET
Session 4: Checkpoint Inhibitors for All
Presenter:
Ramez Eskander, MD
– University of California, San Diego
12:45 PM – 1:00 PM
ET
Session 4: Individualized Checkpoint Inhibitors
Presenter:
Debra Richardson, MD
– Stephenson Cancer Center, University of Oklahoma Health Sciences Center
1:00 PM – 1:15 PM
ET
Live Panel Discussion
Moderator:
Kathleen N. Moore, MD, MS
– Stephenson Cancer Center, University of Oklahoma Health Sciences Center
Presenter:
Ramez Eskander, MD
– University of California, San Diego
Presenter:
Debra Richardson, MD
– Stephenson Cancer Center, University of Oklahoma Health Sciences Center
1:15 PM – 1:30 PM
ET
Break
1:15 PM – 1:30 PM
ET
Break
1:30 PM – 2:30 PM
ET
Non-CME Innovation Theater
1:30 PM – 2:30 PM
ET
Non-CME Innovation Theater
2:30 PM – 2:45 PM
ET
Break
2:30 PM – 2:45 PM
ET
Break
2:45 PM – 3:20 PM
ET
Session 5: Updates in Front Line Adjuvant and Metastatic Treatment of Endometrial Cancer
2:45 PM – 3:20 PM
ET
Session 5: Updates in Front Line Adjuvant and Metastatic Treatment of Endometrial Cancer
Presenter:
Floor Backes, MD
– The Ohio State University Wexner Medical Center and James Cancer Hospital
3:20 PM – 3:30 PM
ET
Live Q&A
3:20 PM – 3:30 PM
ET
Live Q&A
Moderator:
Kathleen N. Moore, MD, MS
– Stephenson Cancer Center, University of Oklahoma Health Sciences Center
Presenter:
Floor Backes, MD
– The Ohio State University Wexner Medical Center and James Cancer Hospital
3:30 PM – 3:45 PM
ET
Break
3:30 PM – 3:45 PM
ET
Break
3:45 PM – 4:20 PM
ET
Session 6: Emerging Developments in Recurrent (2L and beyond) Endometrial Cancer
3:45 PM – 4:20 PM
ET
Session 6: Emerging Developments in Recurrent (2L and beyond) Endometrial Cancer
Presenter:
Kathleen N. Moore, MD, MS
– Stephenson Cancer Center, University of Oklahoma Health Sciences Center
4:20 PM – 4:30 PM
ET
Live Q&A
4:20 PM – 4:30 PM
ET
Live Q&A
Presenter:
Kathleen N. Moore, MD, MS
– Stephenson Cancer Center, University of Oklahoma Health Sciences Center
4:30 PM – 4:45 PM
ET
Break
4:30 PM – 4:45 PM
ET
Break
4:45 PM – 5:20 PM
ET
Session 7: Updates in Molecular Testing and Front-Line Treatment in Ovarian Cancer
4:45 PM – 5:20 PM
ET
Session 7: Updates in Molecular Testing and Front-Line Treatment in Ovarian Cancer
Presenter:
Bradley Monk, MD
– Director, Principal Investigator, Community Research Development, HonorHealth Research Institute
5:20 PM – 5:30 PM
ET
Live Q&A
5:20 PM – 5:30 PM
ET
Live Q&A
Moderator:
Kathleen N. Moore, MD, MS
– Stephenson Cancer Center, University of Oklahoma Health Sciences Center
Presenter:
Bradley Monk, MD
– Director, Principal Investigator, Community Research Development, HonorHealth Research Institute
Thursday, November 2, 2023
8:00 AM – 8:15 AM
ET
Welcome and Introduction
8:00 AM – 8:15 AM
ET
Welcome and Introduction
8:15 AM – 8:50 AM
ET
Session 8: Advanced Ovarian Cancer Therapies: PARP Inhibitors and Beyond
8:15 AM – 8:50 AM
ET
Session 8: Advanced Ovarian Cancer Therapies: PARP Inhibitors and Beyond
Presenter:
Debra Richardson, MD
– Stephenson Cancer Center, University of Oklahoma Health Sciences Center
8:50 AM – 9:00 AM
ET
Live Q&A
8:50 AM – 9:00 AM
ET
Live Q&A
Moderator:
Kathleen N. Moore, MD, MS
– Stephenson Cancer Center, University of Oklahoma Health Sciences Center
Presenter:
Debra Richardson, MD
– Stephenson Cancer Center, University of Oklahoma Health Sciences Center
9:00 AM – 9:15 AM
ET
Break
9:00 AM – 9:15 AM
ET
Break
9:15 AM – 9:50 AM
ET
Session 9: Relapsing Ovarian Cancer: Expert Advice for Selecting New and Emerging Targeted Therapeutics
9:15 AM – 9:50 AM
ET
Session 9: Relapsing Ovarian Cancer: Expert Advice for Selecting New and Emerging Targeted Therapeutics
Presenter:
Colleen McCormick, MD, MPH
– University of New Mexico Cancer Center
9:50 AM – 10:00 AM
ET
Live Q&A
9:50 AM – 10:00 AM
ET
Live Q&A
Moderator:
Kathleen N. Moore, MD, MS
– Stephenson Cancer Center, University of Oklahoma Health Sciences Center
Presenter:
Colleen McCormick, MD, MPH
– University of New Mexico Cancer Center
10:00 AM – 10:15 AM
ET
Break
10:00 AM – 10:15 AM
ET
Break
10:15 AM – 11:15 AM
ET
Non-CME Innovation Theater
10:15 AM – 11:15 AM
ET
Non-CME Innovation Theater
11:15 AM – 11:30 AM
ET
Break
11:15 AM – 11:30 AM
ET
Break
11:30 AM – 12:05 PM
ET
Session 10: Food Insecurity in Oncology
11:30 AM – 12:05 PM
ET
Session 10: Food Insecurity in Oncology
Presenter:
Christina Washington, MD
– University of Oklahoma
12:05 PM – 12:15 PM
ET
Live Q&A
12:05 PM – 12:15 PM
ET
Live Q&A
Moderator:
Kathleen N. Moore, MD, MS
– Stephenson Cancer Center, University of Oklahoma Health Sciences Center
Presenter:
Christina Washington, MD
– University of Oklahoma
12:15 PM – 12:30 PM
ET
Break
12:15 PM – 12:30 PM
ET
Break
12:30 PM – 1:05 PM
ET
Session 11: Updates from Recent Meetings
12:30 PM – 1:05 PM
ET
Session 11: Updates from Recent Meetings
Presenter:
Ramez Eskander, MD
– University of California, San Diego
1:05 PM – 1:15 PM
ET
Live Q&A
1:05 PM – 1:15 PM
ET
Live Q&A
Presenter:
Ramez Eskander, MD
– University of California, San Diego
1:15 PM – 1:30 PM
ET
Break
1:15 PM – 1:30 PM
ET
Break
1:30 PM – 2:30 PM
ET
Non-CME Innovation Theater
1:30 PM – 2:30 PM
ET
Non-CME Innovation Theater
2:30 PM – 2:45 PM
ET
Break
2:30 PM – 2:45 PM
ET
Break
2:45 PM – 3:20 PM
ET
Session 12: Collateral Damage: Side Effects of Breast Cancer Treatment
2:45 PM – 3:20 PM
ET
Session 12: Collateral Damage: Side Effects of Breast Cancer Treatment
Presenter:
Marissa Marti-Smith, MSN, APRN, AGNP-C, AOCNP
– Texas Oncology -Baylor Charles A. Sammons Cancer Center
3:20 PM – 3:30 PM
ET
Live Q&A
3:20 PM – 3:30 PM
ET
Live Q&A
Moderator:
Erika P. Hamilton, MD
– Sarah Cannon Research Institute (SCRI)
Presenter:
Marissa Marti-Smith, MSN, APRN, AGNP-C, AOCNP
– Texas Oncology -Baylor Charles A. Sammons Cancer Center
3:30 PM – 3:45 PM
ET
Break
3:30 PM – 3:45 PM
ET
Break
3:45 PM – 4:30 PM
ET
Session 13: Debate: Should We Quantify HER-2 Expression for Use of TDXd and Other ADCs?
3:45 PM – 4:00 PM
ET
Session 13: Debate: Should We Quantify HER-2 Expression for Use of TDXd and Other ADCs? - NO
Presenter:
Paolo Tarantino, MD
– Dana-Farber Cancer Institute, Harvard Medical School
4:00 PM – 4:15 PM
ET
Session 13: Debate: Should We Quantify HER-2 Expression for Use of TDXd and Other ADCs? - YES
Presenter:
Giuseppe Curigliano, Professor MD PhD
– European Insitute of Oncology, IRCCS and University of Milano
4:15 PM – 4:30 PM
ET
Live Panel Discussion
Moderator:
Erika P. Hamilton, MD
– Sarah Cannon Research Institute (SCRI)
Panelist:
Giuseppe Curigliano, Professor MD PhD
– European Insitute of Oncology, IRCCS and University of Milano
Panelist:
Paolo Tarantino, MD
– Dana-Farber Cancer Institute, Harvard Medical School
4:30 PM – 4:45 PM
ET
Break
4:30 PM – 4:45 PM
ET
Break
4:45 PM – 5:20 PM
ET
Session 14: CDK4/6 Inhibitors Results in Early and Metastatic Breast Cancer
4:45 PM – 5:20 PM
ET
Session 14: CDK4/6 Inhibitors Results in Early and Metastatic Breast Cancer
Presenter:
Komal Jhaveri, MD, FACP
– Memorial Sloan Kettering Cancer Center
5:20 PM – 5:30 PM
ET
Live Q&A
5:20 PM – 5:30 PM
ET
Live Q&A
Presenter:
Komal Jhaveri, MD, FACP
– Memorial Sloan Kettering Cancer Center
Friday, November 3, 2023
8:00 AM – 8:15 AM
ET
Welcome and Introduction
8:00 AM – 8:15 AM
ET
Welcome and Introduction
8:15 AM – 8:50 AM
ET
Session 15: Special Topics in HR+ Breast Cancer
8:15 AM – 8:50 AM
ET
Session 15: Special Topics in HR+ Breast Cancer
Presenter:
Kevin Kalinsky, MD, MS
– Winship Cancer Institute at Emory University
8:50 AM – 9:00 AM
ET
Live Q&A
8:50 AM – 9:00 AM
ET
Live Q&A
Moderator:
Erika P. Hamilton, MD
– Sarah Cannon Research Institute (SCRI)
Presenter:
Kevin Kalinsky, MD, MS
– Winship Cancer Institute at Emory University
9:00 AM – 9:15 AM
ET
Break
9:00 AM – 9:15 AM
ET
Break
9:15 AM – 10:00 AM
ET
Session 16: ER-Positive Targeted Therapy: PI3, AKT, mTOR, etc
9:15 AM – 10:00 AM
ET
Session 16: ER-Positive Targeted Therapy: PI3, AKT, mTOR, etc
Presenter:
Joyce O'Shaughnessy, MD
– Baylor Charles A. Sammons Cancer Center/ Baylor University Medical Center/ Texas Oncology
10:00 AM – 10:15 AM
ET
Break
10:00 AM – 10:15 AM
ET
Break
10:15 AM – 11:15 AM
ET
Non-CME Innovation Theater
10:15 AM – 11:15 AM
ET
Non-CME Innovation Theater
11:15 AM – 11:30 AM
ET
Break
11:15 AM – 11:30 AM
ET
Break
11:30 AM – 12:05 PM
ET
Session 17: HER2-Positive Metastatic Breast Cancer: Where are We Headed?
11:30 AM – 12:05 PM
ET
Session 17: HER2-Positive Metastatic Breast Cancer: Where are We Headed?
Presenter:
Sara Hurvitz, MD
– University of California, Los Angeles
11:30 AM – 12:15 PM
ET
Session 17: HER2-Positive Metastatic Breast Cancer: Where are We Headed?
12:05 PM – 12:15 PM
ET
Live Q&A
Moderator:
Erika P. Hamilton, MD
– Sarah Cannon Research Institute (SCRI)
Presenter:
Sara Hurvitz, MD
– University of California, Los Angeles
12:15 PM – 12:30 PM
ET
Break
12:15 PM – 12:30 PM
ET
Break
12:30 PM – 1:05 PM
ET
Session 18: Immunotherapy for Breast Cancer
12:30 PM – 1:05 PM
ET
Session 18: Immunotherapy for Breast Cancer
Presenter:
Javier Cortes, MD, PhD
– International Breast Cancer Center , IBCC
1:05 PM – 1:15 PM
ET
Live Q&A
1:05 PM – 1:15 PM
ET
Live Q&A
Moderator:
Erika P. Hamilton, MD
– Sarah Cannon Research Institute (SCRI)
Presenter:
Javier Cortes, MD, PhD
– International Breast Cancer Center , IBCC
1:15 PM – 1:30 PM
ET
Break
1:15 PM – 1:30 PM
ET
Break
1:30 PM – 2:05 PM
ET
Session 19: ADCs: A New Technology
1:30 PM – 2:05 PM
ET
Session 19: ADCs: A New Technology
Presenter:
Giuseppe Curigliano, Professor MD PhD
– European Insitute of Oncology, IRCCS and University of Milano
2:05 PM – 2:15 PM
ET
Live Q&A
2:05 PM – 2:15 PM
ET
Live Q&A
Moderator:
Erika P. Hamilton, MD
– Sarah Cannon Research Institute (SCRI)
Presenter:
Giuseppe Curigliano, Professor MD PhD
– European Insitute of Oncology, IRCCS and University of Milano
2:15 PM – 2:30 PM
ET
Break
2:15 PM – 2:30 PM
ET
Break
2:30 PM – 3:15 PM
ET
Session 20: Novel Endocrine Backbones
2:30 PM – 3:15 PM
ET
Session 20: Novel Endocrine Backbones
Presenter:
Erika P. Hamilton, MD
– Sarah Cannon Research Institute (SCRI)
3:15 PM – 3:30 PM
ET
Break
3:15 PM – 3:30 PM
ET
Break
3:30 PM – 4:05 PM
ET
Session 21: HER2-Low Breast Cancer: Limits of Testing and Where To Go From Here
3:30 PM – 4:05 PM
ET
Session 21: HER2-Low Breast Cancer: Limits of Testing and Where To Go From Here
Presenter:
Paolo Tarantino, MD
– Dana-Farber Cancer Institute, Harvard Medical School
4:05 PM – 4:15 PM
ET
Live Q&A
4:05 PM – 4:15 PM
ET
Live Q&A
Moderator:
Erika P. Hamilton, MD
– Sarah Cannon Research Institute (SCRI)
Presenter:
Paolo Tarantino, MD
– Dana-Farber Cancer Institute, Harvard Medical School
On-Demand
30 minutes
Review of Cellular Therapies under Study in Gynecologic Cancers
30 minutes
Review of Cellular Therapies under Study in Gynecologic Cancers
Presenter:
Roisin E. O'Cearbhaill, MD
– Memorial Sloan Kettering Cancer Center
30 minutes
Sexual Side Effects of Treatment
30 minutes
Sexual Side Effects of Treatment
Presenter:
Don S. Dizon, MD
– Brown University
45 minutes
Antibody Drug Conjugates in Gynecologic Cancers: Available Agents and Toxicity Mitigation
45 minutes
Antibody Drug Conjugates in Gynecologic Cancers: Available Agents and Toxicity Mitigation
Presenter:
Kathleen N. Moore, MD, MS
– Stephenson Cancer Center, University of Oklahoma Health Sciences Center
45 minutes
Best Practices for Uterine Sarcomas
45 minutes
Best Practices for Uterine Sarcomas
Presenter:
Gary Schwartz, MD
– Case Comprehensive Cancer Center
45 minutes
Care of Special Populations
45 minutes
Care of Special Populations
Presenter:
BJ Rimel, MD
– Cedars-Sinai Medical Center
45 minutes
Update in Vulvar and Vaginal Cancers
45 minutes
Update in Vulvar and Vaginal Cancers
Presenter:
Brian Slomovitz, MD
– Florida International University
2:00 PM – 2:30 PM
ET
Biosimilars in Breast Cancer Therapy
2:00 PM – 2:30 PM
ET
Biosimilars in Breast Cancer Therapy
Presenter:
William Gradishar, MD, FASCO, FACP
